Nephrotic syndrome and kidney failure due to immunocomplex-mediated renal damage in a patient with Waldenström's Macroglobulinemia: a case report

Castro, Héctor; Valenzuela, Rafael; Ruiz, Phillip; Lenz, Oliver; Monrroy, Mauricio

doi:10.1186/1757-1626-1-333

Cited by 4 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 25 Renal insufficiency in WM can be also secondary to immune-mediated glomerulonephritis or minimal change disease. 26 Fat biopsy and/or evaluation of the bone marrow biopsy with Congo red can help establish the diagnosis. Mass spectrometry should be ideally performed to characterize the amyloid protein.…”

Section: Clinical Manifestationsmentioning

confidence: 99%

Differential Diagnosis of Waldenström’s Macroglobulinemia and Early Management: Perspectives from Clinical Practice

Cingam¹,

Sidana²

2022

BLCTT

View full text Add to dashboard Cite

Waldenström’s Macroglobulinemia (WM) is a clonal B-lymphocyte neoplasm characterized by the presence of IgM monoclonal protein and ≥10% bone marrow involvement with lymphoplasmacytic cells. Several mature B-cell and plasma cell disorders can potentially produce monoclonal IgM immunoglobulin and hence, careful consideration of the differential diagnosis is vital. Clinico-pathological features, immunophenotype, and MYD88 mutation status help distinguish WM from other plasma cell and lymphoproliferative disorders. Treatment is only indicated in patients symptomatic from adenopathy or organomegaly, neuropathy, hyper viscosity, cryoglobulinemia, cold agglutinin disease, cytopenia’s or amyloidosis. Alkylators (cyclophosphamide, bendamustine) in combination with anti-CD20 antibodies and novel targeted agents including Bruton tyrosine kinase (BTK) inhibitors like ibrutinib are the mainstay of frontline treatment in symptomatic WM.

show abstract

Section: Clinical Manifestationsmentioning

confidence: 99%